This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Whitcomb, B. P. Articles by Goodfellow, P. J. Search for Related Content PubMed PubMed Citation Articles by Whitcomb, B. P. Articles by Goodfellow, P. J.

Frequent HOXA11 and THBS2 Promoter Methylation, and a Methylator Phenotype in Endometrial Adenocarcinoma¹

Division of Gynecologic Oncology, Departments of Obstetrics and Gynecology [B. P. W., D. G. M., T. J. H., J. S. R., R. K. G.] and Surgery [P. J. G.], Washington University School of Medicine, St. Louis, Missouri 63110

Purpose: This study was designed to determine whether there is a methylator phenotype in stage I and II endometrioid endometrial adenocarcinoma, and if so, whether methylation correlates with recurrence.

Experimental Design: Bisulfite-converted DNAs from 24 stage I and II primary cancers (12 recurrent and 12 nonrecurrent), and 5 endometrial cancer cell lines were analyzed for methylation in the promoter regions of seven genes. A methylation index (MeI) was calculated for each tumor. Frequent HOXA11 and THBS2 methylation prompted analysis of case-matched bloods and 25 additional nonrecurrent primary cancers. Statistical analysis included Fisher’s exact and Student t tests.

Results: Rates of methylation in the initial tumor series were as follows: HOXA11, 70.8%; THBS2, 62.5%; MLH1, 33.3%; CTNNB1, 16.7%; VDR, 4.2%; CDKN2A, 4.2%; and THBS1, 0%. There was no difference in the MeI of recurrent and nonrecurrent cases. However, cell lines had higher mean MeI. High rates of HOXA11 and THBS2 methylation were confirmed in the additional nonrecurrent tumors. None of the 24 case-matched bloods had HOXA11 methylation, whereas three blood DNAs showed THBS2 methylation. There was a statistically significant difference in the rate of HOXA11 methylation in recurrent and nonrecurrent tumors (P = 0.0167).

Conclusions: Endometrial adenocarcinomas have a methylator phenotype. No correlation between MeI and clinicopathologic variables in early stage tumors was observed. High rates of methylation were found in the HOXA11 and THBS2 promoter regions. HOXA11 promoter methylation was significantly more frequent in recurrent than nonrecurrent cases. HOXA11 methylation in early stage endometrial cancer is associated with poor outcome.

This article has been cited by other articles:

				N Horree, P J van Diest, P van der Groep, D M D S Sie-Go, and A P M Heintz Progressive derailment of cell cycle regulators in endometrial carcinogenesis J. Clin. Pathol., January 1, 2008; 61(1): 36 - 42. [Abstract] [Full Text] [PDF]

				I. Zighelboim, P. J. Goodfellow, F. Gao, R. K. Gibb, M. A. Powell, J. S. Rader, and D. G. Mutch Microsatellite Instability and Epigenetic Inactivation of MLH1 and Outcome of Patients With Endometrial Carcinomas of the Endometrioid Type J. Clin. Oncol., May 20, 2007; 25(15): 2042 - 2048. [Abstract] [Full Text] [PDF]

				I. Zighelboim, P. J. Goodfellow, A. P. Schmidt, K. C. Walls, M. A. Mallon, D. G. Mutch, P. S. Yan, T. H.-M. Huang, and M. A. Powell Differential Methylation Hybridization Array of Endometrial Cancers Reveals Two Novel Cancer-Specific Methylation Markers Clin. Cancer Res., May 15, 2007; 13(10): 2882 - 2889. [Abstract] [Full Text] [PDF]

				J. L. Hecht and G. L. Mutter Molecular and Pathologic Aspects of Endometrial Carcinogenesis J. Clin. Oncol., October 10, 2006; 24(29): 4783 - 4791. [Abstract] [Full Text] [PDF]

				D. Furlan, I. Carnevali, B. Marcomini, R. Cerutti, E. Dainese, C. Capella, and C. Riva The High Frequency of De novo Promoter Methylation in Synchronous Primary Endometrial and Ovarian Carcinomas. Clin. Cancer Res., June 1, 2006; 12(11): 3329 - 3336. [Abstract] [Full Text] [PDF]

				H. Yoshida, R. Broaddus, W. Cheng, S. Xie, and H. Naora Deregulation of the HOXA10 Homeobox Gene in Endometrial Carcinoma: Role in Epithelial-Mesenchymal Transition Cancer Res., January 15, 2006; 66(2): 889 - 897. [Abstract] [Full Text] [PDF]